Other scientific trials in clients with non-Hodgkin's lymphoma [24] and individuals with advanced malignancy [14] have demonstrated also that zosuquidar did not considerably influence the pharmacokinetics of doxorubicin and had reasonable outcomes around the pharmacokinetics of vincristine. These clinical trials permitted that zosuquidar could safely administrated with daunorubicin, d... https://edgarc332oak6.wikitron.com/user